High-resolution metabolomics determines the mode of onset of type 2 diabetes in a 3-year prospective cohort study

  • Authors:
    • Yeseung Lee
    • Aryo Dimas Pamungkas
    • Carl Angelo D. Medriano
    • Jinsung Park
    • Seri Hong
    • Sun Ha Jee
    • Youngja H. Park
  • View Affiliations

  • Published online on: November 21, 2017     https://doi.org/10.3892/ijmm.2017.3275
  • Pages: 1069-1077
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Type 2 diabetes mellitus (DM) is a progressive disease and the rate of progression from non-diabetes to DM varies considerably between individuals, ranging from a few months to many years. It is important to understand the mechanisms underlying the progression of diabetes. In the present study, a high-resolution metabolomics (HRM) analysis was performed to detect potential biomarkers and pathways regulating the mode of onset by comparing subjects who developed and did not develop type 2 DM at the second year in a 3-year prospective cohort study. Metabolic profiles correlated with progression to DM were examined. The subjects (n=98) were classified into four groups: Control (did not develop DM for 3 years), DM (diagnosed with DM at the start of the study), DM onset at the third year and DM onset at the second year. The focus was on the comparison of serum samples of the DM groups with onset at the second and third year from the first year, where these two groups had not developed DM, yet. Analyses involved sample examination using liquid chromatography-mass spectrometry-based HRM and multivariate statistical analysis of the data. Metabolic differences were identified across all analyses with the affected pathways involved in metabolism associated with steroid biosynthesis and bile acid biosynthesis. In the first year, higher levels of cholesterol {mass-to charge ratio (m/z) 369.35, (M+H-H2O)+}, 25-hydroxycholesterol [m/z 403.36, (M+H)+], 3α,7α-dihydroxy-5β-cholestane [m/z 443.33, (M+K)+], 4α-methylzymosterol-4-carboxylate [m/z 425.34, (M+H‑H2O)+], and lower levels of 24,25-dihydrolanosterol [m/z 429.40, (M+H)+] were evident in the group with DM onset at the second year compared with those in the group with DM onset at the third year. These results, with a focus on the cholesterol biosynthesis pathway, point to important aspects in the development of DM and may aid in the development of more effective means of treatment and prevention.
View Figures
View References

Related Articles

Journal Cover

February-2018
Volume 41 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee Y, Pamungkas AD, Medriano CA, Park J, Hong S, Jee SH and Park YH: High-resolution metabolomics determines the mode of onset of type 2 diabetes in a 3-year prospective cohort study. Int J Mol Med 41: 1069-1077, 2018.
APA
Lee, Y., Pamungkas, A.D., Medriano, C.A., Park, J., Hong, S., Jee, S.H., & Park, Y.H. (2018). High-resolution metabolomics determines the mode of onset of type 2 diabetes in a 3-year prospective cohort study. International Journal of Molecular Medicine, 41, 1069-1077. https://doi.org/10.3892/ijmm.2017.3275
MLA
Lee, Y., Pamungkas, A. D., Medriano, C. A., Park, J., Hong, S., Jee, S. H., Park, Y. H."High-resolution metabolomics determines the mode of onset of type 2 diabetes in a 3-year prospective cohort study". International Journal of Molecular Medicine 41.2 (2018): 1069-1077.
Chicago
Lee, Y., Pamungkas, A. D., Medriano, C. A., Park, J., Hong, S., Jee, S. H., Park, Y. H."High-resolution metabolomics determines the mode of onset of type 2 diabetes in a 3-year prospective cohort study". International Journal of Molecular Medicine 41, no. 2 (2018): 1069-1077. https://doi.org/10.3892/ijmm.2017.3275